GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer - PubMed
5 hours ago
- #Prostate cancer
- #Genome-wide association study
- #Radium-223
- Radium-223 dichloride improves survival in bone-metastatic castration-resistant prostate cancer, but individual responses vary.
- A genome-wide association study identified the germline variant rs1568679 in MEIS2 as significantly associated with a ≥30% decline in prostate-specific antigen.
- Patients with the rs1568679 CC genotype had better PSA decline, longer symptomatic skeletal event-free survival, radiographic progression-free survival, and overall survival.
- The rs1568679 CC genotype remained an independent favorable prognostic factor after adjusting for clinical factors.
- Pathway analysis linked MEIS2 to DNA repair and genomic stability, suggesting a role in susceptibility to radium-223's effects.
- rs1568679 may serve as a biomarker for favorable response to radium-223, aiding in personalized treatment strategies.